Injesta solution for injections 1% ampoules 1 ml. №5

Description

Injesta №5 Storage
active substance: progesterone;

1 ml of solution contains progesterone in terms of 100% of the substance 10 mg or 25 mg;

excipients: 2.5% solution – benzyl benzoate, ethyl oleate; 1% solution – ethyl oleate.

Injesta №5 Dosage form
Solution for injection.

Injesta №5 Pharmacotherapeutic group
Progestogens. ATC code G03D A04.

Indication
Amenorrhea, dysfunctional (anovulatory) uterine bleeding; endocrine infertility, including due to corpus luteum insufficiency; miscarriage, oligomenorrhea, algodysmenorrhea (against the background of hypogonadism).

Contraindication
Liver disease, hepatic and renal failure, hepatitis, predisposition to thrombosis, active venous or arterial thromboembolism, severe thrombophlebitis or a history of these conditions, nervous disorders with depression, porphyria. Malignant tumors of the breast and genitals. Ectopic pregnancy or a stillborn pregnancy in the anamnesis, vaginal bleeding of unknown origin, condition after abortion.

Method of application and dosage
The drug is administered intramuscularly or subcutaneously. At dysfunctional uterine bleedings the drug to appoint on 5-15 mg daily within 6-8 days. If you have previously had the uterine lining scraped off, start the injection in 18-20 days. If it is not possible to scrape, inject Ingest even during bleeding. When Ingesta is used during bleeding, its temporary (for 3-5 days) increase may be observed, due to which patients with moderate and severe anemia are recommended to have a blood transfusion (200-250 ml). At the stopped bleeding it is not necessary to interrupt treatment earlier than 6 days. If the bleeding has not stopped after 6-8 days of treatment, further administration of Ingesta is impractical.

In case of hypogonadism and amenorrhea, treatment should begin with the use of estrogenic drugs in order to achieve sufficient endometrial proliferation. Immediately after the end of the use of estrogenic drugs to prescribe Ingest 5 mg daily or 10 mg every other day for 6-8 days.

In case of algodysmenorrhea, Ingesta treatment should be started 6-8 days before menstruation. The drug is administered daily at 5-10 mg for 6-8 days. The course of treatment can be repeated several times.

To prevent and eliminate the risk of miscarriage, inject 10-25 mg of Injesta daily or every other day until the complete disappearance of symptoms of miscarriage. At a usual miscarriage to enter drug to IV month of pregnancy.

The highest single and daily dose for adults when administered intramuscularly is 25 mg (2.5 ml of 1% solution or 1 ml of 2.5% solution).